Search Results

You are looking at 201 - 210 of 1,331 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Craig S. Schneider, Robert A. Oster, Aparna Hegde, Michael C. Dobelbower, John M. Stahl, and Adam J. Kole

chemotherapy. Most patients received CFRT (64.3%), whereas SBRT (21.8%) and HFRT (13.9%) were less common. The most commonly used RT fractionation regimen for each category can be found in supplemental eTable 1 . Table 1. Patient Characteristics

Full access

Xiaoxiao Lu, Qing Huang, Linda Wu, Bruno Emond, Shaun P. Forbes, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, and Kerry A. Rogers

evaluated time to discontinuation (TTD) and characteristics associated with TTD for first-line (1L) V+G. Methods : The nationwide Flatiron Health electronic health record-derived de-identified database (4/11/15-6/30/21) was used to select adults with CLL

Full access

Ata S. Moshiri and Paul Nghiem

staining introduced in the 1990s) ( Figure 1 ). 2 MCC characteristically presents as a solitary pink or purple nodule ( Figure 2 ) that typically has several of the features summarized in the mnemonic “AEIOU”: A symptomatic (eg, painless, nonpruritic), E

Full access

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

knowledge regarding the typical characteristics of ICI-related esophagitis and the appropriate treatments for this condition. In this retrospective study, we aimed to characterize esophagitis associated with the use of ICIs and describe its clinical

Full access

Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov

, including race, SES, and age, given the need to more deeply characterize test uptake in these groups over time. Population characteristics were analyzed using chi-square tests. Among those who received the 21-gene assay, kernel density estimates of the RS

Full access

Antoine Eskander, Qing Li, Jiayue Yu, Julie Hallet, Natalie G. Coburn, Anna Dare, Kelvin K.W. Chan, Simron Singh, Ambica Parmar, Craig C. Earle, Lauren Lapointe-Shaw, Monika K. Krzyzanowska, Timothy P. Hanna, Antonio Finelli, Alexander V. Louie, Nicole Look Hong, Jonathan C. Irish, Ian J. Witterick, Alyson Mahar, Christopher W. Noel, David R. Urbach, Daniel I. McIsaac, Danny Enepekides, and Rinku Sutradhar

. Data Sources The analysis was performed using data held at the ICES (previously known as the Institute for Clinical Evaluative Sciences). Demographic characteristics, vital status, and date of death for all individuals covered under the Ontario Health

Full access

Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian, Jun Lu, Xue-Yan Zhang, Hui-Min Wang, Bo Yan, Bo Zhang, Shu-Yuan Wang, Fang Hu, Chang-Hui Li, Hua Zhong, and Bao-Hui Han

. Receiver operating characteristic (ROC) curve that plotted sensitivity against 1-specificity of bTMB and rate of DCB was assessed by generating the area under the curve (AUC) for the training set. The accuracy of bTMB for predicting OS was assessed using

Full access

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich

outcomes. Baseline age, sex, race, tumor characteristics, serum lactate dehydrogenase and C-reactive protein (CRP) levels, lung immune prognostic index (LIPI), neutrophil-to-lymphocyte ratio, and various subpopulations of white cells were evaluated for

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger, and James O. Armitage

distinguish between the entities. 4 Clinical characteristics might also be helpful in making the distinction, including no history of CML or myeloproliferative disorder, no evidence of chronic or accelerated phases of CML after induction therapy, and no

Full access

Jordan K. Schaefer, Amro Elshoury, Victoria R. Nachar, Michael B. Streiff, and Ming Y. Lim

General Anticoagulant Characteristics Anticoagulants recommended in current CAT treatment guidelines include low-molecular-weight heparin (LMWH), warfarin, and in recent years, the direct oral anticoagulants (DOACs). 4 Fondaparinux is also occasionally